## BEAM: Beam Therapeutics Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.9% in lower entry zone (3.0-6.0%), top quartile (82nd pct) cross-sectional ranking. Caution: MRS_5 (-0.3%) diverging from MRS_10, watch for reversal. Outperforming sector by 7.4%. Caution: momentum weakening (-12.1% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($23.84)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Evercore ISI Remains a Buy on Beam Therapeutics (BEAM)**
- Source: The Globe and Mail | 20251209T180852 | Somewhat-Bullish | Relevance: 98%
-  Evercore ISI analyst Cory Kasimov maintained a Buy rating on Beam Therapeutics (BEAM) with a $35.00 price target. This re-affirms positive sentiment despite a recent Hold rating from TR | OpenAI â€“ 4o and negative insider sentiment. Beam Therapeutics reported a quarterly revenue of $9.7 million and a GAAP net loss of $112.73 million for the quarter ending September 30.

**2. Beam Therapeutics stock rises on promising sickle cell therapy data**
- Source: Investing.com | 20251208T084900 | Bullish | Relevance: 98%
-  Beam Therapeutics Inc. (NASDAQ:BEAM) saw its stock rise after presenting updated positive data from its BEACON Phase 1/2 clinical trial for ristoglogene autogetemcel (risto-cel) in sickle cell disease. The data showed durable hemoglobin F induction and hemoglobin S reduction, with a favorable safety profile and efficient cell collection. The company is progressing towards a regulatory filing for the treatment.

**3. Beam Therapeutics edges higher after new sickle cell therapy results**
- Source: MSN | 20251208T161004 | Bullish | Relevance: 97%
- Beam Therapeutics (BEAM) saw its shares rise after presenting new data for its sickle cell disease therapy, BEAM-101, at the American Society of Hematology meeting. Updated results from the Phase 1/2 clinical trial showed an almost complete elimination of sickle cells and improved total hemoglobin levels, particularly fetal hemoglobin. The company also announced plans to initiate a global Phase 3 study in mid-2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Evercore ISI Gr | $35 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Evercore ISI Gr | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.02M) |
| Sells | 5 ($0.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 2 |

**Top Holders:**
- FMR, LLC: 11.5% (-9.8%)
- ARK Investment Manag: 10.9% (+24.8%)
- Farallon Capital Man: 9.9% (+0.5%)
- Vanguard Group Inc: 9.1% (-4.7%)
- Blackrock Inc.: 8.0% (+1.8%)

### Key Risks

1. High beta (2.22) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 7.0x requires aggressive growth execution.
3. High short interest (22.8%, 8.2 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 7.04 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (6.0x), low leverage (D/E 0.36). Institutional flow bullish (6 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 2.22 |
| 52W Range | $13.53 - $35.25 |
| Short Interest | 22.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 7.04 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 16.0% to 3.9% (-12.1% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 82nd percentile. MRS_5 (-0.3%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 7.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.93% (CS: 83) | Strong |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 0.47 | Bullish |
| vs SMA20 | 1.135x | Above |
| vs SMA50 | 1.095x | Above |
| vs SMA200 | 1.306x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $27.40
- **Stop Loss:** $23.84 (13.0% risk)
- **Target:** $32.74 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 140
- **Position Value:** $3,836.00
- **Portfolio %:** 3.84%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-24 (Est: $-1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.01 | $-1.10 | -8.9% |
| 2025Q2 | $-1.09 | $-1.00 | +8.4% |
| 2025Q1 | $-1.17 | $-1.24 | -5.9% |
| 2024Q4 | $-1.22 | $-1.09 | +10.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*